[Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
D001545:Benserazide; D002262:Carboxy-Lyases / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005069:Evaluation Studies as Topic; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006173:Gymnastics; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa; D010300:Parkinson Disease / Q000188:drug therapy* / Q000628:therapy; D013070:Speech Therapy
D004338:Drug Combinations; D006834:Hydrazines; C005177:benserazide, levodopa drug combination; D007980:Levodopa; D004295:Dihydroxyphenylalanine; D001545:Benserazide; D002262:Carboxy-Lyases
Erfahrungsbericht über die Behandlung des Parkinson-Syndroms mit dem Kombinationspräparat L-Dopa + Dekarboxylasehemmer (Ro 8-0576.